We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
13 own
21 watching
Current Price
$2.32
$-0.09
(-3.73%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
704.22M
52-Week High
5.13
52-Week Low
1.95
Average Volume
3.04M
Dividend Yield
--
P/E Ratio
84.6746
Market Capitalization704.22M
52-Week High5.13
52-Week Low1.95
Average Volume3.04M
Dividend Yield--
P/E Ratio84.6746
What does the Stockal+Disclaimer.pdf do?
Amneal Pharmaceuticals, Inc., formerly known as Atlas Holdings, Inc. (the "Company"), was formed along with its wholly owned subsidiary, K2 Merger Sub Corporation, a Delaware corporation ("Merger Sub"), on October 4, 2017, for the purpose of facilitating the combination of Impax Laboratories, Inc. (now Impax Laboratories, LLC), a Delaware corporation then listed on the Nasdaq Stock Market ("Impax") and Amneal Pharmaceuticals LLC, a Delaware limited liability company ("Amneal").
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Business Wire
14days ago
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the Company) today announced that the management team will attend the following investor conferences: Piper Sandler 34th Annual Healthcare Conference December 1, 2022 New York, New York 41st Annual J.P. Morgan Healthcare Conference January 10, 2023 San...
Business Wire
26days ago
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for IPX203 for the treatment of Parkinsons disease (PD). IPX203 is a novel, oral formulation of carbidopa/levodopa (CD/LD) extended-release...
Zolmax
3 months ago
Russell Investments Group Ltd. increased its position in shares of Amneal Pharmaceuticals, Inc. (NYSE:AMRX Get Rating) by 8.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 518,245 shares of the companys ...
Zolmax
4 months ago
Amneal Pharmaceuticals (NYSE:AMRX Get Rating) had its price objective cut by The Goldman Sachs Group from $4.50 to $4.00 in a report issued on Monday morning, Stock Target Advisor reports. They currently have a buy rating on the stock. Separately, Barclays decreased their price objective on shares ...
Business Wire
4 months ago
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) announced its results today for the second quarter ended June 30, 2022. Solid second quarter results reflect topline growth across all three segments and meaningful acceleration in performance from the first quarter. Our core...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$2.32
$-0.09
(-3.73%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00